AbbVie: A Pharmaceutical Giant with a Terrific Track Record for Long-Term Returns

AbbVie, a pharmaceutical giant, has a strong track record of beating the S&P 500 returns since its split from Abbott Laboratories in 2013. The company protected its Humira medicine from biosimilars, innovated with new products, resorted to acquisitions, and significantly grew its dividends. With a deep pipeline of products and a history of raising payouts for over 50 years, AbbVie is a Dividend King that can continue to help investors establish a solid foundation for their financial future.